A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs
Clinical trial NCT04908202 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04908202
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-13
- Primary completion
- 2024-09-05
- Enrollment
- 670
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.